What's The BUZZ?

Market News, Products, Services, and Trends

Advertisement

Endo Launches First and Only Generic Version of RAVICTI® (glycerol phenylbutyrate) Oral Liquid in the United States

Endo Launches First and Only Generic Version of RAVICTI® (glycerol phenylbutyrate) Oral Liquid in the United States

Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today the launch of a generic version of Amgen’s RAVICTI® (glycerol phenylbutyrate), 1.1 gm/mL oral liquid, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.

Endo’s glycerol phenylbutyrate is the first and currently the only FDA-approved generic version of RAVICTI® available in the U.S.

“This first-to-market launch of generic RAVICTI® oral liquid is a meaningful milestone for Endo and important for our Generics business as we near the planned spin-off of Par Health,” said Scott Sims, Senior Vice President and General Manager, Endo Injectable Solutions and Generics. “It expands access for patients and providers, and reinforces our commitment to quality, reliability, and leadership in complex generics.” Read More >

Endo

Endo News & Announcements

Through our long-standing work in endocrinology, orthopedics, and urology, as well as in hospital systems and with retail generic medications, we have developed an unmatched understanding of those we serve. We will never stop learning how to make a real difference in people’s lives. We partner with hospitals and healthcare systems to reduce complexity through life-enhancing solutions, innovating together to add value where it matters—from manufacturing to treatment—so that healthcare providers can focus on patient care. We deliver high-quality, affordable generic medicines to patients in need through excellence in development, manufacturing, and commercialization. Drawing from over four decades of experience in the U.S. generic pharmaceutical market, we have built a well-established reputation for compliance and exceptional customer service.

RXinsider Staff

Posted by: RXinsider Staff

RXinsider is a multimedia publishing and technology company offering print publications, digital platforms, events, and content creation services to the B2B pharmacy market.

SUBSCRIBE

Name
Subscription Choices
Checkboxes

Request information from Endo Launches First and Only Generic Version of RAVICTI® (glycerol phenylbutyrate) Oral Liquid in the United States

Name
Address
Subscribe